VRAX (Virax Biolabs Group) FCF Margin %: -145,100.00% (As of Sep. 2025)


VRAX Virax Biolabs Group Ltd VRAX
37 GF Score
Price $3.09
GF Value $1.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Virax Biolabs Group FCF Margin %?

Virax Biolabs Group VRAX -0.64% 37 FCF Margin % is -145,100.00% as of Sep. 2025. GuruFocus rates VRAX with a GF Score™ of 37/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 948 Biotechnology companies, Virax Biolabs Group ranks worse than 98.95% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Virax Biolabs Group's Free Cash Flow for the six months ended in Sep. 2025 was $-2.90 Mil. Virax Biolabs Group's Revenue for the six months ended in Sep. 2025 was $0.00 Mil. Therefore, Virax Biolabs Group's FCF Margin % for the quarter that ended in Sep. 2025 was -145,100.00%.

As of today, Virax Biolabs Group's current FCF Yield % is -239.67%.

The historical rank and industry rank for Virax Biolabs Group's FCF Margin % or its related term are showing as below:

VRAX' s FCF Margin % Range Over the Past 10 Years
Min: -196766.67   Med: -4750.64   Max: -475.81
Current: -196766.67

During the past 6 years, the highest FCF Margin % of Virax Biolabs Group was -475.81%. The lowest was -196766.67%. And the median was -4750.64%.

VRAX's FCF Margin % is ranked worse than
98.95% of 948 companies
in the Biotechnology industry
Industry Median: -83.535 vs VRAX: -196766.67

Virax Biolabs Group FCF Margin % Related Terms

Virax Biolabs Group FCF Margin % Historical Data

* Premium members only.

The historical data trend for Virax Biolabs Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group FCF Margin % Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
FCF Margin %
Get a 7-Day Free Trial -475.81 0.00 -48,422.22 -4,750.64 -86,133.33

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,587.01 -3,886.25 -43,340.00 -300,100.00 -145,100.00

VRAX vs BBLG, PKTX, OGEN: FCF Margin % Comparison

For the Biotechnology subindustry, Virax Biolabs Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's FCF Margin % falls into.


VRAX
37GF Score
Virax Biolabs Group Ltd VRAX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virax Biolabs Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Virax Biolabs Group's FCF Margin for the fiscal year that ended in Mar. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-5.168/0.006
=-86,133.33 %

Virax Biolabs Group's FCF Margin for the quarter that ended in Sep. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-2.902/0.002
=-145,100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -145,100.00% mean?
Virax Biolabs Group (VRAX) has a FCF Margin % of -145,100.00% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Virax Biolabs Group and its competitors. According to the industry distribution chart, Virax Biolabs Group ranks #938 out of 948 companies in the Biotechnology industry, placing it in the top 98.9%.
Is Virax Biolabs Group's FCF Margin % too high?
Virax Biolabs Group's current FCF Margin % is -145,100.00%. Based on the distribution chart, Virax Biolabs Group ranks #938 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's FCF Margin % compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #938 out of 948 companies for FCF Margin %. This places Virax Biolabs Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current FCF Margin % is -145,100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current FCF Margin % is -145,100.00%. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current FCF Margin % is -145,100.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15. GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.

Key valuation signals for VRAX:

  • FCF Margin %: -145,100.00%
  • GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score

Get the complete analysis for VRAX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price
$1.15
GF Value